A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer’s disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial

Abstract Background Research into the neurobiological underpinnings of learning and memory has demonstrated the cognitive-enhancing effects associated with diverse classes of phosphodiesterase (PDE) inhibitors. Specific PDE inhibitors have been identified to improve neuronal communication through se...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Nina Possemis, Frans Verhey, Jos Prickaerts, Arjan Blokland, Inez Ramakers
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2024-03-01
Σειρά:	Trials
Θέματα:	Mild cognitive impairment Dementia Alzheimer Cognitive dysfunction Roflumilast Phosphodiesterase 4
Διαθέσιμο Online:	https://doi.org/10.1186/s13063-024-08001-3
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!